Xiansheng Pharmaceutical announced that the company and Jiaxing Andikang Biotechnology Co., Ltd. cooperated with Jiaxing Andikang Biotechnology Co., Ltd. to market the new anti-influenza drug mandeuloxavir granules were accepted by the State Drug Administration to treat uncomplicated influenza A and influenza B in children aged 2 to 11. It is the first innovative anti-influenza virus drug for pediatric patients that has successfully completed phase III clinical trials and declared for marketing.

Zhitongcaijing · 09/03/2025 10:09
Xiansheng Pharmaceutical announced that the company and Jiaxing Andikang Biotechnology Co., Ltd. cooperated with Jiaxing Andikang Biotechnology Co., Ltd. to market the new anti-influenza drug mandeuloxavir granules were accepted by the State Drug Administration to treat uncomplicated influenza A and influenza B in children aged 2 to 11. It is the first innovative anti-influenza virus drug for pediatric patients that has successfully completed phase III clinical trials and declared for marketing.